Trial Profile

Phase II trial investigating the tolerability and preliminary efficacy of inecalcitol in patients with chronic lymphocytic leukaemia, not yet requiring immuno-chemotherapy but at high risk of disease progression.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Feb 2014 Interim results reported in a Hybrigenics media release.
04 Feb 2014 To date, 24 patients have been enrolled, according to a Hybridgenics media release.
28 Jan 2014 Based on preliminary clinical data, inecalcitrol has been designated as an orphan drug for chronic lymphocytic leukaemia in Europe, according to a Hybrigenics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com